Motesanib Plus Carboplatin, Paclitaxel Extended Survival in NSCLC | Lung Cancer Dispatch | Scoop.it

"The addition of motesanib to carboplatin and paclitaxel improved OS, PFS and response rates in patients with nonsquamous non–small cell lung cancer, according to results of a phase 3 study.


"The subset analysis of the MONET1 trial included 227 Asian patients with stage IIIb/IV or recurrent disease who had not received prior systemic therapy for advanced NSCLC."